35.28
price up icon2.11%   0.73
after-market 시간 외 거래: 35.28
loading
전일 마감가:
$34.55
열려 있는:
$33.95
하루 거래량:
640.38K
Relative Volume:
0.94
시가총액:
$2.17B
수익:
$87.56M
순이익/손실:
$-167.47M
주가수익비율:
-15.08
EPS:
-2.34
순현금흐름:
$-148.20M
1주 성능:
+6.07%
1개월 성능:
+33.84%
6개월 성능:
-24.08%
1년 성능:
-2.81%
1일 변동 폭
Value
$33.95
$35.98
1주일 범위
Value
$32.75
$35.98
52주 변동 폭
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
명칭
Kymera Therapeutics Inc
Name
전화
857-285-5314
Name
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
직원
188
Name
트위터
Name
다음 수익 날짜
2025-02-21
Name
최신 SEC 제출 서류
Name
KYMR's Discussions on Twitter

KYMR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KYMR
Kymera Therapeutics Inc
35.28 2.17B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-13 개시 Citigroup Buy
2024-12-10 개시 BTIG Research Buy
2024-12-06 개시 BMO Capital Markets Market Perform
2024-12-02 업그레이드 Wells Fargo Equal Weight → Overweight
2024-11-18 개시 Stephens Overweight
2024-09-09 재개 Leerink Partners Outperform
2024-08-26 업그레이드 Wolfe Research Peer Perform → Outperform
2024-04-22 개시 Oppenheimer Outperform
2024-02-15 개시 Wolfe Research Peer Perform
2024-01-04 업그레이드 JP Morgan Neutral → Overweight
2024-01-03 다운그레이드 BofA Securities Buy → Neutral
2023-12-19 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-06-30 개시 Truist Buy
2023-05-05 업그레이드 Raymond James Mkt Perform → Outperform
2022-12-06 다운그레이드 Credit Suisse Outperform → Neutral
2022-11-08 개시 Raymond James Mkt Perform
2022-08-15 개시 Jefferies Buy
2022-08-03 개시 Goldman Buy
2022-07-20 개시 SVB Leerink Mkt Perform
2022-04-28 개시 Credit Suisse Outperform
2022-03-10 개시 JP Morgan Neutral
2022-02-10 개시 Wells Fargo Overweight
2021-09-30 개시 B. Riley Securities Neutral
2021-09-30 개시 Stifel Buy
2021-09-10 다운그레이드 BofA Securities Buy → Neutral
2021-05-21 개시 UBS Buy
2021-04-14 개시 Berenberg Buy
2020-12-04 개시 H.C. Wainwright Buy
2020-09-15 개시 BofA Securities Neutral
2020-09-15 개시 Cowen Outperform
2020-09-15 개시 Guggenheim Buy
2020-09-15 개시 Morgan Stanley Equal-Weight
모두보기

Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스

pulisher
May 02, 2025

Kymera Therapeutics Inc’s results are impressive - uspostnews.com

May 02, 2025
pulisher
May 02, 2025

Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX

May 02, 2025
pulisher
May 01, 2025

Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025
pulisher
May 01, 2025

Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025
pulisher
Apr 28, 2025

Closing Figures Unveiled: Kymera Therapeutics Inc (KYMR) Drop -7.60, Closes at 27.37 - DWinneX

Apr 28, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Why Kymera Therapeutics (KYMR) Stock is Moving Today - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Why Kymera Therapeutics Stock Crushed it This Week - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

Kymera Therapeutics Inc (KYMR) Performance and Fundamentals Dashboard tells a completely different story - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

Kymera Therapeutics Inc [KYMR] Shares Rise 9.32 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

KYMR’s Stock Market Adventure: -16.58% YTD Growth Amidst Volatility - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

Daily Market Movement: Kymera Therapeutics Inc (KYMR) Sees a 9.32 Increase, Closing at 33.56 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 F - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 Financials | KYMR Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Kymera Unveils Revolutionary Oral Drug Program Targeting Untapped Autoimmune Disease Pathway - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

Is Kymera Therapeutics Inc (KYMR) worth investing in despite its overvalued state? - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times

Apr 22, 2025
pulisher
Apr 22, 2025

Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan

Apr 22, 2025
pulisher
Apr 18, 2025

Kymera Therapeutics Inc (KYMR) Stock: A Year of Declines and Increases - investchronicle.com

Apr 18, 2025
pulisher
Apr 17, 2025

Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 12, 2025

Investor’s Delight: Kymera Therapeutics Inc (KYMR) Closes Strong at 33.27, Up 0.76 - DWinneX

Apr 12, 2025
pulisher
Apr 11, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 06, 2025
pulisher
Apr 01, 2025

(KYMR) Trading Report - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia

Mar 31, 2025
pulisher
Mar 28, 2025

Kymera Therapeutics identifies new STAT6 degraders - BioWorld MedTech

Mar 28, 2025
pulisher
Mar 27, 2025

Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 21, 2025

Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - The AM Reporter

Mar 18, 2025
pulisher
Mar 15, 2025

Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Citigroup starts coverage of Kymera with $52 PT - TradingView

Mar 13, 2025
pulisher
Mar 11, 2025

(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025
pulisher
Mar 07, 2025

Why Kymera Therapeutics’ Stock is Making Waves - TipRanks

Mar 07, 2025

Kymera Therapeutics Inc (KYMR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):